Condition
Chimeric Antigen Receptor T-cell Therapy
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Not Yet Recruiting1
Unknown1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06890091Not Yet Recruiting
Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma
NCT05190653Not ApplicableRecruiting
Early Integration of Palliative and Supportive Care in Cellular Therapy
NCT06041815Unknown
Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
Showing all 3 trials